Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Transfusion of Rh-incompatible blood Age: Adult Condition: For 2.5 - 15.0 mL Rh-positive red blood cells |
Dose: Intramuscular – 100 IU (20 mcg) per mL of Rh-positive red blood cell exposure Note: Round up to the next whole syringe. Administer within 72 hours of suspected or proven exposure to Rh-positive red blood cells. |
|
Indication: Transfusion of Rh-incompatible blood Age: Adult Condition: greater than 15.0 mL Rh-positive red blood cells |
Dose: Intramuscular – 20 mcg per mL of Rh-positive red blood cell exposure Note: Additional doses are indicated when the patient has been exposed to greater than 15 mL of Rh-positive red blood cells. Round up to the next whole syringe. Multiple doses may be administered at the same time or at spaced intervals, as long as the total dose is administered within three days of exposure. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Immune thrombocytopenic purpura Age: Children |
Dose: intravenous – 250 international units/kg Frequency: single injection Note: administered over 3 to 5 minutes |
Administration
- For hospital use only
- Must be given by healthcare professional
Side Effect
- The most frequently reported AEs are anti-D formation and injection site reactions
- such as swelling
- induration
- redness and mild pain or warmth
- Possible systemic reactions are skin rash
- body aches or a slight elevation in temperature
- Severe systemic allergic reactions are extremely rare
- Patients should be observed for at least 20 minutes after administration
- Patients who are Rh-positive or have received Rh-positive red blood cells may result in signs and symptoms of a hemolytic reaction
- including fever
- back pain
- nausea and vomiting
- hypo- or hypertension
- hemoglobinuria/emia
- elevated bilirubin and creatinine and decreased haptoglobin
- Intravascular haemolysis
- Anaphylaxis reactions
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Live vaccines
|
Should only be admin at least 3 mth after the last dose of immunoglobulin admin
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Rh-Positive Individuals
|
Product ineffective and potentially harmful
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Details coming soon
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.